Skip to main content
Back to homepage
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Coverage Analysts
SEC Filings
SEC Filings
Annual Reports & Proxies
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Menu
Press Releases
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Coverage Analysts
SEC Filings
SEC Filings
Annual Reports & Proxies
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
November 08, 2022
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 07, 2022
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 03, 2022
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
November 02, 2022
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
November 01, 2022
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
October 31, 2022
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
September 21, 2022
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
September 16, 2022
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
September 06, 2022
ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
August 15, 2022
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
August 09, 2022
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 02, 2022
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
July 27, 2022
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
July 20, 2022
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
July 11, 2022
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
July 08, 2022
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
July 01, 2022
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
June 29, 2022
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
June 13, 2022
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
June 10, 2022
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
June 01, 2022
ADC Therapeutics to Present at the Jefferies Healthcare Conference
May 12, 2022
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
May 09, 2022
ADC Therapeutics Announces CEO Transition
May 09, 2022
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 04, 2022
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 03, 2022
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
April 04, 2022
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
March 17, 2022
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
March 03, 2022
ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
March 01, 2022
ADC Therapeutics to Participate in Cowen’s 42nd Annual Health Care Conference
February 24, 2022
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
February 17, 2022
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
February 08, 2022
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
February 02, 2022
ADC Therapeutics to Participate in Guggenheim Oncology Conference
January 20, 2022
ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022
January 18, 2022
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan